Regulatory action is now expected in September 2020
News
Gov’t launches public info campaign for track and trace
It will reiterate the need for those who have been close to someone testing positive for coronavirus to self-isolate
First patient dosed in bemcentinib COVID-19 trial
Bemcentinib was selected as the first candidate to be tested as part of the UK ACcelerating COVID-19 Research & Development platform (ACCORD) study
Roche’s Tecentriq/Avastin combo wins US approval
Tecentriq in combination with Avastin is the first and only cancer immunotherapy regimen cleared to treat unresectable or metastatic liver cancer
Sanofi’s Sarclisa cleared in Europe for multiple myeloma
Multiple myeloma is the second most common blood cancer, with around 40,000 new cases per year in Europe
AbbVie files Rinvoq for psoriatic arthritis
Rinvoq is a selective and reversible JAK inhibitor being studied in several immune-mediated inflammatory diseases
Iterum hit by failure of anti-infective sulopenem
The company is now mulling over its future, which might include sale of the business, restructure, or dissolving and liquidating assets
New US approval for AZ’ Brilinta
New Brilinta indication expands treatment to high-risk coronary patients without a history of stroke or heart attack
PIONEER COVID-19 trial wins funding injection from LifeArc
The funds will enable researchers to investigate the science around the trial, including why coronavirus affects some people more than others
Coronavirus bottleneck leaves 2m waiting for cancer care
2.1 million people are waiting for breast, bowel or cervical screening
Lynparza backed by CHMP for BRCA-mutated pancreatic cancer
Lynparza is the only PARP inhibitor to show patient benefit in a Phase III trial in this setting, says AZ
UK study highlights potential of genetic screening for prostate cancer
Genetic ‘barcoding’ in GP surgeries can identify men at higher risk of prostate cancer, researchers claim
New centre to tackle impact of ethnicity and race on health
The NHS Race and Health Observatory will be hosted by the NHS Confederation
Pfizer’s Ibrance ‘unlikely’ to hit key early breast cancer goal
The trial is unlikely to show a statistically significant improvement in invasive disease-free survival
New vaccine for Ebola among CHMP recommendations
The vaccine could be Janssen’s first to win EU approval
